Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -28.65%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-28.65%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+31.80%
vs the sector median at left
Incannex Healthcare Limited
Market Cap
$37.73M
Return on Equity (ROE)
-28.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.11M
Return on Equity (ROE)
14.51%
TTM Avg
6.28%
3Y Avg
-34.57%
5Y Avg
-35.24%
Market Cap
$36.61M
Return on Equity (ROE)
-160.05%
TTM Avg
-184.57%
3Y Avg
-168.71%
5Y Avg
-141.15%
Market Cap
$38.98M
Return on Equity (ROE)
-140.36%
TTM Avg
-216.21%
3Y Avg
-112.57%
5Y Avg
-76.80%
Market Cap
$36.28M
Return on Equity (ROE)
-819.34%
TTM Avg
-116.46%
3Y Avg
-74.90%
5Y Avg
-96.78%
Market Cap
$36.31M
Return on Equity (ROE)
-476.77%
TTM Avg
-979.99%
3Y Avg
-646.46%
5Y Avg
-421.61%
Market Cap
$39.15M
Return on Equity (ROE)
-83.03%
TTM Avg
-44.32%
3Y Avg
5.07%
5Y Avg
17.23%
Market Cap
$35.71M
Return on Equity (ROE)
N/A
TTM Avg
333.35%
3Y Avg
376.86%
5Y Avg
270.78%
Market Cap
$35.56M
Return on Equity (ROE)
-161.63%
TTM Avg
-60.21%
3Y Avg
-26.37%
5Y Avg
-20.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $37.73M | -28.65% | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $38.11M | 14.51% | 6.28% | -34.57% | -35.24% |
| Edesa Biotech, Inc. (EDSA)vs › | $36.61M | -160.05% | -184.57% | -168.71% | -141.15% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.98M | -140.36% | -216.21% | -112.57% | -76.80% |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | -819.34% | -116.46% | -74.90% | -96.78% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.31M | -476.77% | -979.99% | -646.46% | -421.61% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.15M | -83.03% | -44.32% | 5.07% | 17.23% |
| EUDA Health Holdings Limited (EUDA)vs › | $35.71M | N/A | 333.35% | 376.86% | 270.78% |
| DocGo Inc. (DCGO)vs › | $35.56M | -161.63% | -60.21% | -26.37% | -20.13% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.19M | -154.06% | -1.75% | 68.54% | 60.27% |
ROE
-28.6%
ROA
-26.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-06-30 | -197.23% |
